Available by Consultation

Semaglutide injection 0.25–2.5 mg/mL

A compounded semaglutide option available only through provider consultation in limited patient-specific circumstances. Compounded medications are not FDA-approved. FDA has tightened 503A compounding rules for GLP-1 products.

BPC-157 (Body Protection Compound-157)

A research-stage peptide available only through provider consultation. Not FDA-approved. Listed on FDA 503A Category 2 list. Human clinical data remains limited.

GHK-Cu (Copper Peptide) topical serum

A copper-peptide formulation discussed for selected skin concerns, with evidence and regulatory status that vary by product and use.

Thymosin Beta-4 injection

A research-stage peptide discussed with explicit disclosure that it is not FDA-approved and that human evidence remains limited.

Thymosin Alpha-1 injection 1.6 mg

A peptide that has been studied in immune-related settings, but is not FDA-approved in the United States for consumer self-selection on Varus.

Tirzepatide injection 2.5–15 mg/mL

A compounded tirzepatide option available only through provider consultation in limited patient-specific circumstances. Compounded medications are not FDA-approved. FDA has tightened 503A compounding rules for GLP-1 products.

Nicotinamide Adenine Dinucleotide (NAD+) injection

An NAD+ formulation discussed for selected patients, with limited evidence for broad energy, recovery, or longevity claims.

Finasteride 0.1% / Minoxidil 6% topical solution

A compounded topical finasteride/minoxidil formulation discussed for selected patients. There is no FDA-approved topical finasteride product.

CJC-1295 with DAC + Ipamorelin injection

A compounded peptide combination discussed for selected patients with clear disclosure that it is not FDA-approved and that human evidence for body-composition or recovery claims is limited.

AOD-9604 injection

A research-stage peptide derived from a growth-hormone fragment. It is not FDA-approved, and human evidence for weight-management use is limited.

L-Glutathione injection 200 mg/mL

A glutathione formulation discussed for selected patients, with evidence that varies by indication and no assumption of broad wellness or skin-brightening benefit.

Selank nasal spray 0.15%

A research-stage intranasal peptide discussed with explicit evidence limitations. It is not FDA-approved in the United States.

Semax nasal spray 1%

A research-stage intranasal peptide discussed with explicit evidence limitations. It is not FDA-approved in the United States.

MOTS-C injection

A mitochondrial-derived peptide being studied in early metabolic and exercise-related research. It is not FDA-approved, and evidence remains limited.